Cytokinetics, Incorporated fell 12.7% on Thursday, November 5, 2026, on 6,774,600 shares, 3.4 times its average daily volume. Headlines around the move:
Cytokinetics, Incorporated (CYTK:NASDAQ) closed at $53.69 on November 6, 2026, down 3.35% on the day. The stock trades 39.2% below its 52-week high of $88.31 and 0.3% above its 52-week low of $53.55. Over the past year, it lost 10.8%. Cytokinetics, Incorporated is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 6, 2025, CYTK closed higher on 121 days (48%). Its best day was May 5, 2026 (+16.71%) and its worst was November 5, 2026 (-12.66%). The stock moved 10% or more in a single session 3 times. It opened at least 5% above the previous day's high 1 time.
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. The company is preparing for the commercialization of Tirasemtiv in North America and Europe, as well as has granted an option to Astellas Pharma Inc. for development and commercialization in other countries. The company has strategic alliances with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator that is in two ongoing Phase II clinical trials enrolling patients with spinal muscular atrophy and chronic obstructive pulmonary disease, as wel...
Find more stocks like CYTK with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.